Amarantus Reports Second Quarter 2015 Financial Results and Business Overview
August 17, 2015 08:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus Announces Adjournment of Annual Meeting
August 07, 2015 17:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Aug. 7, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID
August 05, 2015 08:50 ET
|
Amarantus BioScience Holdings, Inc.
Latest preclinical data in the peer-reviewed journal 'Movement Disorders' support previous nonclinical and clinical findings that eltoprazine is effective against Parkinson's Disease L-dopa...
Amarantus Announces Adjournment of Annual Meeting
August 03, 2015 17:30 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds
August 03, 2015 06:00 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
July 29, 2015 07:35 ET
|
Amarantus BioScience Holdings, Inc.
- MSPrecise next generation sequencing assay supports identification of multiple sclerosis patients with 84% accuracy -
- Results from this study were not combined with oligoclonal banding (OCB)...
Amarantus Diagnostics Establishes Strategic Advisory Committee
July 27, 2015 07:35 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, July 27, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests for multiple sclerosis and Alzheimer's disease...
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)
July 22, 2015 10:30 ET
|
Amarantus BioScience Holdings, Inc.
LymPro discriminates Alzheimer's disease (AD) from healthy controls with comparable accuracy to clinical diagnosis reference standard
Data corroborate previously published...
Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
July 20, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, July 20, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns
July 15, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, July 15, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...